Paul Richardson¹, Albert Oriol², Meral Beksac³, Anna Marina Liberati⁴, Monica Galli⁵, Fredrik Schjesvold⁶, Jindriska Lindsay⁷, Katja Weisel⁸, Darrell White⁹, Thierry Facon¹⁰, Jesus San Miguel¹¹, Kazutaka Sunami¹², Peter O Gorman¹³, Pieter Sonneveld¹⁴, Pawel Robak¹⁵, Sergey Semochkin¹⁶, Steve Schey¹⁷, Xin Yu¹⁸, Thomas Doerr¹⁸, Amine Bensmaine¹⁸, Tsvetan Biyukov¹⁹, Sanae Sakurai²⁰, Mohamed Zaki¹⁸, Kenneth Anderson¹, Meletios Dimopoulos²¹ (1.Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America, 2.Institut Catala d Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain, 3.Ankara University, Cebeci Yerleskesi, Dikimevi, Republic of Turkey, 4.University of Perugia, Terni, Italian Republic, 5.A.O. Papa Giovanni XXIII, U.O. di Ematologia, Bergamo, Italian Republic, 6.Oslo University Hospital, Oslo, Kingdom of Norway, 7.East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom of Great Britain and Northern Ireland, 8.University Hospital of Tuebingen, Tuebingen, Federal Republic of Germany, 9.Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Canada, 10.Service des Maladies du Sang, Hopital Claude Huriez, Lille, French Republic, 11.Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain, 12.National Hospital Organization Okayama Medical Center, Okayama, Japan, 13.Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland, 14.Erasmus MC Cancer Institute, Rotterdam, Kingdom of the Netherlands, 15.Medical University of Lodz, Lodz, Republic of Poland, 16.Pirogov Russian National Research Medical University, Moscow, Russian Federation, 17.Department of Hematology, King's College London, London, United Kingdom of Great Britain and Northern Ireland, 18.Celgene Corporation, Summit, United States of America, 19.Celgene International Sarl, Boudry, Swiss Confederation, 20.Celgene K.K., Tokyo, Japan, 21National and Kapodistrian University of Athens, Athens, Republic of Cyprus)

Andrew Spencer¹, Vania Hungria², Roman Hajek³, Katja Weisel⁴, Francesca Gay⁵, Meral Beksac⁶, Piruntha Thiyagarajah⁷, Himal Amin⁸, Xiang Qin⁹, Jordan M. Schecter⁸, Pieter Sonneveld¹⁰ (1.Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Clayton, Australia, 2.Irmandade Da Santa Casa De Misericordia De Sao Paulo, Sao Paulo, Federative Republic of Brazil, 3.Fakultni nemocnice Ostrava, Ostrava-Poruba-Poruba, Czech Republic, 4.Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tubingen, Federal Republic of Germany, 5.Division of Hematology, University of Torino, A.O.U. San Giovanni Battista, Torino, Italian Republic, 6.Ankara University, Department of Hematology, Ankara, Republic of Turkey, 7.Janssen Research & Development, LLC, High Wycombe, United Kingdom of Great Britain and Northern Ireland, 8.Janssen Research & Development, LLC, Raritan, United States of America, 9.Janssen Research & Development, LLC, Spring House, United States of America, 10.Department of Hematology, Erasmus MC, Rotterdam, Kingdom of the Netherlands)

Camille V. Edwards¹, Divaya Bhutani², Markus Mapara², Jai Radhakrishnan³, Sofia Shames⁴, Mathew S. Maurer⁴, Siyang Leng², Alan Solomon⁵, Suzanne Lentzsch², Andrew Eisenberger² (1.Department of Hematology and Oncology, Boston Medical Center, Boston, United States of America, 2.Division of Hematology and Oncology, Columbia University Medical Center, New York, United States of America, 3.Division of Nephrology, Columbia University Medical Center, New York, United States of America, 4.Division of Cardiology, Columbia University Medical Center, New York, United States of America, 5.Graduate School of Medicine, University of Tennessee, Knoxville, United States of America)

Kenshi Suzuki¹, Michele Cavo², Meletios A. Dimopoulos³, Jesus San-Miguel⁴, Andrzej Jakubowiak⁵, Sung-Soo Yoon⁶, Mark Cook⁷, Mario Boccadoro⁸, P. Joy Ho⁹, Ludek Pour¹⁰, Stefan Knop¹¹, Chantal Doyen¹², Andre Crepaldi¹³, Tamas Masszi¹⁴, Joan Blade¹⁵, Jianping Wang¹⁶, Susan Wroblewski¹⁷, William Deraedt¹⁸, Ming Qi¹⁷, Maria-Victoria Mateos¹⁹ (1.Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan, 2.Seragnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italian Republic, 3.National and Kapodistrian University of Athens, Athens, Hellenic Republic, 4.Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain, 5.University of Chicago Medical Center, Chicago, United States of America, 6.Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, 7.University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom of Great Britain and Northern Ireland, 8.Myeloma Unit, Division of Hematology, University of Torino, Torino, Italian Republic, 9.Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia, 10.University Hospital Brno, Brno, Czech Republic, 11.Wuerzburg University Medical Center, Wuerzburg, Federal Republic of Germany, 12.Universite catholique de Louvain (UcL) CHU UCL Namur, Yvoir, Kingdom of Belgium, 13.Clinica de Tratamento E, Cuiaba, Federative Republic of Brazil, 14.Department of Haematology and Stem Cell Transplantation, St Laszlo Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Republic of Hungary, 15.Servei d'Hematologia, Hospital Clinic de Barcelona, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain, 16.Janssen Research & Development, Raritan, United States of America, 17.Janssen Research & Development, Spring House, United States of America, 18.Janssen Research & Development, Beerse, Kingdom of Belgium, 19.University Hospital of Salamanca/IBSAL, Salamanca, Spain)

Annette Lam¹, Thierry Facon², Meletios A. Dimopoulos³, Maria-Victoria Mateos⁴, Michele Cavo⁵, Bart Heeg⁶, Sophie van Beekhuizen⁶, Marta Pisini⁷, Sandhya Nair⁸, Mary Slavcev¹, Jesus San-Miguel⁹ (1.Janssen Global Services, Raritan, United States of America, 2.Hopital Claude Huriez, CHRU Lille, Lille, France Metropolitan, 3.National and Kapodistrian University of Athens, Athens, Hellenic Republic, 4.University Hospital of Salamanca/IBSAL, Salamanca, Spain, 5.“Seragnoli” Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italian Republic, 6.Ingress Health, Rotterdam, Kingdom of the Netherlands, 7.Janssen EMEA, Kingdom of Belgium, 8.Janssen Research and Development, Beerse, Kingdom of Belgium, 9.Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain)

Aditya Jandial, Kundan Mishra, Deepesh Lad, Ritu Bansal, Gaurav Prakash, Alka Khadwal, Neelam Varma, Pankaj Malhotra (Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, Republic of India)